PFEPfizerRunning, no new patients
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,068 (final count)
- Started
- Dec 30, 2019
- Main results expected
- Dec 2, 2024
- Fully finished
- Dec 2, 2026
- Results posted
- Jan 22, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C
Measured over: From randomization (Day 1) to first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04165317 · record last updated 2026-10-15 · checked 2026-11-09 15:42 UTC